PADCEV: payments to doctors
Payments that named PADCEV as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $7.7M
- Providers
- 12,337
- Transactions
- 59,639
- Average per transaction
- $130
The per-transaction average — $130 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 12,337 providers the average total is $627, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Seagen Inc. | $3,199,308 | 41.3% |
| Astellas Pharma US Inc | $2,265,251 | 29.3% |
| Pfizer | $1,530,258 | 19.8% |
| Astellas Pharma Global Development | $395,672 | 5.1% |
| Astellas Pharma Europe Ltd | $313,089 | 4.0% |
| Astellas Pharma Inc | $31,760 | 0.4% |
| Seattle Genetics, Inc. | $1,783 | 0.0% |
| Array Biopharma Inc | $649 | 0.0% |
| Hospira, Inc. | $19 | 0.0% |